Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Prostate cancer: Time for active surveillance of intermediate-risk disease?

Ahmed HU.

Nat Rev Urol. 2013 Jan;10(1):6-8. doi: 10.1038/nrurol.2012.213. Epub 2012 Nov 13. No abstract available.

PMID:
23147924
2.

Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial.

Lane JA, Donovan JL, Davis M, Walsh E, Dedman D, Down L, Turner EL, Mason MD, Metcalfe C, Peters TJ, Martin RM, Neal DE, Hamdy FC; ProtecT study group.

Lancet Oncol. 2014 Sep;15(10):1109-18. doi: 10.1016/S1470-2045(14)70361-4. Epub 2014 Aug 19. Erratum in: Lancet Oncol. 2014 Oct;15(11):e475.

3.

Ongoing Gleason grade migration in localized prostate cancer and implications for use of active surveillance.

Weiner AB, Etzioni R, Eggener SE.

Eur Urol. 2014 Oct;66(4):611-2. doi: 10.1016/j.eururo.2014.02.051. Epub 2014 Mar 4. No abstract available.

4.

Active surveillance of prostate cancer in African American men.

Silberstein JL, Feibus AH, Maddox MM, Abdel-Mageed AB, Moparty K, Thomas R, Sartor O.

Urology. 2014 Dec;84(6):1255-61. doi: 10.1016/j.urology.2014.06.064. Epub 2014 Oct 3. Review.

PMID:
25283702
5.

Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance.

Satkunasivam R, Kulkarni GS, Zlotta AR, Kalnin R, Trachtenberg J, Fleshner NE, Hamilton RJ, Jewett MA, Finelli A.

J Urol. 2013 Jul;190(1):91-5. doi: 10.1016/j.juro.2013.01.019. Epub 2013 Jan 12.

PMID:
23321581
6.

[Prostatectomy vs. "watchful waiting" in early prostate cancer].

Markun S.

Praxis (Bern 1994). 2014 Jul 23;103(15):909-10. doi: 10.1024/1661-8157/a001714. German. No abstract available.

PMID:
25051936
7.

Management of early prostate cancer.

Horwich A, Parker CC, Huddart RA, Dearnaley DP.

Ann Oncol. 2002;13 Suppl 4:83-7. Review. No abstract available.

PMID:
12401671
8.

Factors Influencing Selection of Active Surveillance for Localized Prostate Cancer.

Liu J, Womble PR, Merdan S, Miller DC, Montie JE, Denton BT; Michigan Urological Surgery Improvement Collaborative.

Urology. 2015 Nov;86(5):901-5. doi: 10.1016/j.urology.2015.08.024. Epub 2015 Sep 7.

PMID:
26358397
9.

Clinical trials: ProtecT-ing against prostate cancer.

Stone L.

Nat Rev Urol. 2014 Nov;11(11):601. doi: 10.1038/nrurol.2014.249. Epub 2014 Sep 9. No abstract available.

PMID:
25201617
10.

Re: Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities.

Ahmed HU, Emberton M.

J Urol. 2008 Aug;180(2):780-1; author reply 781-3. doi: 10.1016/j.juro.2008.04.045. Epub 2008 Jun 13. No abstract available.

PMID:
18555492
11.

Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.

Iremashvili V, Manoharan M, Rosenberg DL, Soloway MS.

BJU Int. 2013 Apr;111(4):574-9. doi: 10.1111/j.1464-410X.2012.11127.x. Epub 2012 May 4.

12.

Predictors of Adverse Pathology in Men Undergoing Radical Prostatectomy Following Initial Active Surveillance.

Reese AC, Feng Z, Landis P, Trock BJ, Epstein JI, Carter HB.

Urology. 2015 Nov;86(5):991-5. doi: 10.1016/j.urology.2015.07.039. Epub 2015 Aug 31.

PMID:
26335496
13.

Editorial comment on: tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer.

Gallina A.

Eur Urol. 2010 Apr;57(4):639. doi: 10.1016/j.eururo.2009.03.008. Epub 2009 Mar 10. No abstract available.

PMID:
19299073
14.

Editorial comment on: tumor grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer.

Yossepowitch O.

Eur Urol. 2010 Apr;57(4):639-40. doi: 10.1016/j.eururo.2009.03.009. Epub 2009 Mar 10. No abstract available.

PMID:
19299071
15.

A systematic overview of radiation therapy effects in prostate cancer.

Nilsson S, Norlén BJ, Widmark A.

Acta Oncol. 2004;43(4):316-81. Review.

PMID:
15303499
16.

Surgery or radiation: what is the optimal management for locally advanced prostate cancer?

Fletcher SG, Theodorescu D.

Can J Urol. 2005 Feb;12 Suppl 1:58-61; discussion 101-2. Review.

PMID:
15780168
17.

Active surveillance for favorable-risk prostate cancer: background, patient selection, triggers for intervention, and outcomes.

Klotz L.

Curr Urol Rep. 2012 Apr;13(2):153-9. doi: 10.1007/s11934-012-0242-4. Review.

PMID:
22477615
18.

Population-Based Assessment of Determining Treatments for Prostate Cancer.

Chamie K, Williams SB, Hu JC.

JAMA Oncol. 2015 Apr;1(1):60-7. doi: 10.1001/jamaoncol.2014.192.

PMID:
26182305
19.

The ProtecT trial: what can we expect?

Roobol MJ, Bokhorst LP.

Lancet Oncol. 2014 Sep;15(10):1046-7. doi: 10.1016/S1470-2045(14)70198-6. Epub 2014 Aug 19. No abstract available. Erratum in: Lancet Oncol. 2014 Oct;15(11):e475.

20.

Highlights from the 97th Annual Meeting of the American Urological Association: Orlando, Florida, May 25-30, 2002.

Johnson L, Lee D.

Clin Prostate Cancer. 2002 Sep;1(2):72-8. No abstract available.

PMID:
15046696

Supplemental Content

Support Center